Regaining compliance with Nasdaq's listing requirements is a significant positive development for Aileron Therapeutics. It removes the immediate risk of delisting, which can have a detrimental effect on stock price and investor confidence. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in the stock price.